

August 17, 2026

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Sub: Communication received from Docon Technologies Private Limited ('Promoter') regarding release of pledge over 7,94,69,696 Equity Shares of Thyrocare Technologies Limited ("Company")

Ref: Disclosure pursuant to Regulations 29(2), 31(2) and 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as received from the Promoter

Dear Sir/Madam,

We wish to inform you that the Company has received a communication from **Docon Technologies Private Limited, Promoter of the Company**, inter alia informing that pursuant to the full redemption and repayment of the Non-Convertible Debentures issued by **API Holdings Limited**, the ultimate holding company of the Company, the pledge created over **7,94,69,696 equity shares** of the Company held by the Promoter has been released.

The Promoter has further informed that, following the aforesaid repayment, API Holdings Limited has no outstanding debt under the said Non-Convertible Debentures and the entire shareholding held by the Promoter in the Company is now free from pledge.

In this regard the Promoter has submitted the requisite disclosures pursuant to Regulations 29(2), 31(2) and 31(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

A copy of the disclosure received from the Promoter is enclosed herewith for your information and taking the same on record.

Yours Faithfully,
For **Thyrocare Technologies Limited**,



Brijesh Kumar
Company Secretary and Compliance Officer

Encl. A/a

DOCON TECHNOLOGIES PRIVATE LIMITED

August 17, 2026

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400 073	

Sub: Release of Pledge on 7,94,69,696 Equity Shares of Thyrocare Technologies Limited ("Thyrocare")

Ref: Disclosures pursuant to Regulations 29(2), 31(2) and Regulation 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir & Madam,

We refer to our earlier disclosures dated September 24, 2025, November 11, 2025, December 05, 2025, March 31, 2026, April 20, 2026 and August 13, 2026 made under Regulations 29(2) and 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST Regulations"), in relation to the encumbrance created by Docon Technologies Private Limited ("Docon"), Promoter of Thyrocare Technologies Limited (the "Company"/"Thyrocare"), pursuant to the Corporate Guarantee extended by Docon to secure the obligations of API Holdings Limited ("API"), the Holding Company, in respect of facilities availed by API through the issuance of unlisted, unrated, secured, redeemable, Non-Convertible Debentures ("NCDs").

In connection with the aforesaid NCDs, Docon had pledged its equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee.

The aforesaid NCDs, having an outstanding principal amount of INR 10,500 million, have been fully redeemed and repaid by API on August 14, 2026.

Consequently, upon the full redemption and repayment of the aforesaid NCDs, the pledge created by Docon over the remaining 7,94,69,696 equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee, has been fully released.


Accordingly, as on August 17, 2026, **the entire pledge created by Docon over its shareholding in equity shares of Thyrocare in connection with the aforesaid NCDs stands fully released.** Further, there is no outstanding pledge or other encumbrance by the promoter over the share capital of Thyrocare.

Pursuant to Regulations 29(2), 31(2) and 31(3) of the SEBI SAST Regulations, please find enclosed the requisite disclosures:

1. Disclosure under Regulation 29(2) of the SEBI (SAST) Regulations – **Annexure I**
2. Disclosure under Regulations 31(2) and 31(3) of the SEBI (SAST) Regulations – **Annexure II**

You are requested to take the above disclosure on record.

For Docon Technologies Private Limited


Madhuri Sudhir Sarangdhar
Company Secretary



DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure I

Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Thyrocare Technologies Limited ("Thyrocare")		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Acquirer: #Docon Technologies Private Limited PAC: API Holdings Limited		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share /voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of:			
a. Shares carrying voting rights	17,30,304	1.09	1.08
b. Shares in the nature of encumbrance (pledge /lien/ non disposal undertaking/ others)	7,94,69,696	49.93	49.79
c. Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
e. Total (a+b+c+d)	8,12,00,000	51.02	50.87
Details of acquisition/sale			
a. Shares carrying voting rights acquired/sold	Nil	Nil	Nil
b. VRs acquired /sold otherwise than by shares	Nil	Nil	Nil
c. Warrants/convertible securities/any other	Nil	Nil	Nil
d. instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold Shares encumbered / invoked /released by the acquirer	7,94,69,696	49.93	49.79
e. Total (a+b+c+/-d)	7,94,69,696	49.93	49.79

DOCON TECHNOLOGIES PRIVATE LIMITED

After the acquisition/sale, holding of:			
a. Shares carrying voting rights	8,12,00,000	51.02	50.87
b. Shares encumbered with the acquirer	Nil	Nil	Nil
c. VRs otherwise than by shares	Nil	Nil	Nil
d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
e. Total (a+b+c+d)	8,12,00,000	51.02	50.87
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Release of pledge over 7,94,69,696 equity shares of Thyrocare Technologies Limited held by Docon Technologies Private Limited (Promoter of Thyrocare Technologies Limited), which had been pledged in favour of Catalyst Trusteeship Limited in connection with the Non-Convertible Debentures ("NCDs") issued by API Holdings Limited.		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	August 17, 2026 (Release of Pledge)		
Equity share capital / total voting capital of the TC before the said acquisition / sale	15,91,65,315 Equity shares having face value of Rs. 10 each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	15,91,65,315 Equity shares having face value of Rs. 10 each		
Total diluted share/voting capital of the TC after the said acquisition	15,96,30,252 equity shares having face value of Rs. 10 each		

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Docon has not acquired any additional equity shares pursuant to the release of the pledge. The release of the pledge was pursuant to the full repayment of the NCDs by API. The repayment of the NCDs was funded, inter alia, through the sale of 1,57,69,696 equity shares of the Company held by Docon and through internal accruals of API.

For and on behalf of **Docon Technologies Private Limited**


Madhuri Sudhir Sarangdhar
 Company Secretary



Date: August 17, 2026

DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure-II

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)					Thyrocare Technologies Limited ("Thyrocare")								
Names of the stock exchanges where the shares of the target company are listed					1. BSE Limited 2. National Stock Exchange of India Limited								
Date of reporting					August 17, 2026								
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked					Promoter: Docon Technologies Private Limited PAC: API Holdings Limited								
Details of the creation of encumbrance*													
Name of the promoter(s) PACs with him*	Promoter holding in the target company (1)		Promoter holding already encumbered (2)		Details of events pertaining to encumbrance (3)							Post event holding of Encumbered shares {creation [(2)+(3)] / release [(2)-(3)] / invocation [(1)-(3)]}	
	Number	% of total share capital	Number	% of total share capital	Type of event {creation / Release / invocation}	Date of creation / release / invocation	Type of encumbrance {pledge / line / non disposal / undertaking / others}	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares Encumbered ***	Number	% of total share capital
Docon Technologies Private	8,12,00,000	51.02	8,12,00,000	51.02	Release of pledge	August 17, 2026	Release of pledge on 7,94,69,696	The shares were pledged as	Release of pledge on 7,94,69,696	49.93	Docon had outstanding pledge over 7,94,69,696 equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture	-	-

DOCON TECHNOLOGIES PRIVATE LIMITED

Limited (“Docon”)							equity shares of Thyrocare Technologies Limited held by Docon Technologies Private Limited (Promoter of Thyrocare Technologies Limited), which had been pledged in favour of Catalyst Trusteeship Limited in connection with the existing Non-Convertible Debentures ("NCDs") issued by API Holdings Limited, pursuant to full redemption and	security for the NCDs issued by API Holdings Limited. The outstanding pledge over 7,94,69,696 equity shares was released by Catalyst Trusteeship Limited, acting as Debenture Trustee pursuant to full redemption and repayment of the NCDs.	equity shares of Thyrocare Technologies Limited held by Docon	Trustee, as security for the obligations of API Holdings Limited in respect of the NCDs issued by API. The aforesaid NCDs, having an outstanding principal amount of INR 10,500 million, were fully redeemed and repaid by API on August 14, 2026. Consequently, upon the full repayment and redemption of the aforesaid NCDs, the pledge created by Docon over 7,94,69,696 equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee, was fully released. The release of the pledge does not result in any change in Docon’s shareholding in Thyrocare. Accordingly, Docon continues to hold 8,12,00,000 equity shares of Thyrocare as on August 17, 2026, representing 51.02% of the total share capital of Thyrocare. Further, no shares held by Docon remain encumbered. Details of NCD Holders to whom repayment was made: <table><tr><th>Sr</th><th>Name of NCDs Holder</th><th>Principal Amount (INR in Mn)</th></tr><tr><td>1</td><td>Poonawalla Fincorp Limited</td><td>918.75</td></tr><tr><td>2</td><td>360 One Income Opportunities Fund - Series 7</td><td>131.25</td></tr><tr><td>3</td><td>Bagla Industries Private Limited</td><td>21.00</td></tr><tr><td>4</td><td>Tata Capital Limited</td><td>2,843.75</td></tr></table>	Sr	Name of NCDs Holder	Principal Amount (INR in Mn)	1	Poonawalla Fincorp Limited	918.75	2	360 One Income Opportunities Fund - Series 7	131.25	3	Bagla Industries Private Limited	21.00	4	Tata Capital Limited	2,843.75	
Sr	Name of NCDs Holder	Principal Amount (INR in Mn)																								
1	Poonawalla Fincorp Limited	918.75																								
2	360 One Income Opportunities Fund - Series 7	131.25																								
3	Bagla Industries Private Limited	21.00																								
4	Tata Capital Limited	2,843.75																								

DOCON TECHNOLOGIES PRIVATE LIMITED

							repayment of the NCDs.				5	Ganesh Polychem Ltd	43.75		
											6	360 One Prime Limited	4,870.25		
											7	Advik Hi Tech Private Limited	29.75		
											8	Micro Labs Limited	59.50		
											9	Sak Industries Private Ltd	151.38		
											10	Ban Labs Private Limited	55.13		
											11	Lake Chemicals P Ltd	29.75		
											12	Sonnet Trade and Investments Pvt Ltd	9.63		
											13	Vara Future LLP	29.75		
											14	Moorjani Ventures Private Limited	29.75		
											15	Medley Pharmaceuticals Limited	29.75		
											16	Bennett Coleman and Company Limited	437.50		
											17	Urmila Behera	12.25		
											18	Warmond Fiduciary Services Limited	12.25		
											19	Warmond Fiduciary Services Limited	22.75		
											20	Warmond Fiduciary Services Limited	22.75		
											21	Warmond Fiduciary Services Limited	5.25		
											22	Mvs Ventures Private Limited	58.62		
											23	Alkram Venture Private Limited	58.62		
											24	Warmond Fiduciary	17.50		

Madhuri Sudhir Sarang



n the target comp.

0.001

done by the compa